Management of albinism: French guidelines for diagnosis and care.
E Moreno-ArteroFanny Morice-PicardD Bremond-GignacI Drumare-BouvetC Duncombe-PouletS Leclerc-MercierH DufresneJ KaplanB JouanneB ArveilerAlain TaiebSmail Hadj RabiaPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2021)
Albinism is a worldwide genetic disorder caused by mutations in at least 20 genes, identified to date, that affect melanin production or transport in the skin, hair and eyes. Patients present with variable degrees of diffuse muco-cutaneous and adnexal hypopigmentation, as well as ocular features including nystagmus, misrouting of optic nerves and foveal hypoplasia. Less often, albinism is associated with blood, immunological, pulmonary, digestive and/or neurological anomalies. Clinical and molecular characterizations are essential in preventing potential complications. Disease-causing mutations remain unknown for about 25% of patients with albinism. These guidelines have been developed for the diagnosis and management of syndromic and non-syndromic forms of albinism, based on a systematic review of the scientific literature. These guidelines comprise clinical and molecular characterization, diagnosis, therapeutic approach and management.
Keyphrases
- optical coherence tomography
- clinical practice
- end stage renal disease
- intellectual disability
- genome wide
- healthcare
- newly diagnosed
- ejection fraction
- systematic review
- chronic kidney disease
- palliative care
- pulmonary hypertension
- peritoneal dialysis
- prognostic factors
- risk factors
- autism spectrum disorder
- pain management
- patient reported outcomes
- blood brain barrier
- gene expression
- transcription factor
- wound healing
- high grade
- chronic pain